Revelation Biosciences, Inc. (REVB)
Revelation Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $1.11, down 1.33% on the session, giving a market capitalisation of $4.4M. On trailing twelve-month figures it carries a trailing P/E of -0.16, a net margin of 0.0%. Its beta of -0.17 implies it has historically moved less than the broad market.
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Revelation Biosciences, Inc. is most often compared with the following Healthcare names: